Biosimilar breast cancer drug trial pulled before it started

NCT ID NCT06884254

Terminated Disease control Sponsor: EirGenix, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study was designed to test whether a biosimilar version of pertuzumab (EG1206A) works as well as the original drug (Perjeta) in people with HER2-positive, hormone receptor-negative early breast cancer. Participants would have received either the biosimilar or the original drug along with standard chemotherapy and trastuzumab before and after surgery. However, the trial was withdrawn before enrolling any patients, so no data were collected.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Pertuzumab (biosimilar EG1206A)
What this could lead to: If successful, this could show that a more affordable biosimilar works as well as the original drug for treating HER2-positive breast cancer.
What could go wrong: The trial was withdrawn before enrolling any participants, so no results are available. Biosimilars may have subtle differences in effectiveness or side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EARLY BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm HER2 positive breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

EARLY BREAST CANCER

Contacts and locations

Locations

Methodist Health System Clinical Research Institute

Dallas, Texas, 75023, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.